Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-329 in Autoimmune Disease
NCT07085104Phase 1Recruiting
- Sponsor
- Allogene Therapeutics
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- CRISPR-Cas9, CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label trial of ALLO-329 in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM) and systemic sclerosis (SSc) (3 arms), sponsored by Allogene Therapeutics. Primary endpoint: Incidence of Dose Limiting toxicities (DLTs) and Other Safety Parameters at 60 months. Started Nov 2025; status: recruiting.
02
Drugs
ALLO-329
03
Conditions
systemic lupus erythematosus (SLE)idiopathic inflammatory myopathy (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07085104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085104.